Description:
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H2 2018

Summary
According to the recently published report 'Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2018'; Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dual specificity protein kinase TTK is an enzyme encoded by the TTK gene. It is associated with cell proliferation, essential for chromosome alignment at the centromere during mitosis and is required for centrosome duplication. It acts as critical mitotic checkpoint protein for accurate segregation of chromosomes during mitosis.

The report 'Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2018' outlays comprehensive information on the Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 4 respectively.

Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Breast Cancer, Metastatic Breast Cancer, Solid Tumor, Colorectal Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and Pancreatic Ductal Adenocarcinoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope

- The report provides a snapshot of the global therapeutic landscape for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)
- The report reviews Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine
Protein Kinase or TTK or EC 2.7.12.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

**Table Of Contents:**

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage

**Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Overview**

**Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Therapeutics Development**

Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes

**Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Therapeutics Assessment**

Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

**Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Companies Involved in Therapeutics Development**

Bayer AG
Boston Pharmaceuticals Inc
Les Laboratoires Servier SAS
Nerviano Medical Sciences Srl
Netherlands Translational Research Center BV
Pfizer Inc

**Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Drug Profiles**

BAY-1217389 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-172722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-271850 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFI-402257 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
empesertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTRC-00660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTRC-15010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-81694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mps1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Tyrosine Threonine Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or
Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dormant Products
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or
Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Discontinued Products
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or
Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Product Development
Milestones
Featured News & Press Releases
Apr 20, 2017: Experimental drug could lead to potent combination in breast and other cancers
Sep 24, 2015: Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1
inhibitor, in a first in Human clinical trial
Oct 29, 2012: Nerviano Medical Sciences To Present Four Posters At 24th EORTC-NCI-AACR
Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Boston Pharmaceuticals Inc, H2 2018
Pipeline by Les Laboratoires Servier SAS, H2 2018
Pipeline by Nerviano Medical Sciences Srl, H2 2018
Pipeline by Netherlands Translational Research Center BV, H2 2018
Pipeline by Pfizer Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Companies Mentioned:
Bayer AG
Boston Pharmaceuticals Inc
Les Laboratoires Servier SAS
Nerviano Medical Sciences Srl
Netherlands Translational Research Center BV
Pfizer Inc

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless an Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other
person or persons outside the corporate location for which the publication is purchased.  
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.  
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.  
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.  
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

---

**Drug Pipeline**

No. 1101, Golden Square, 3rd Floor,  
24th Main, J P Nagar, 1st Phase,  
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

---

**NAVIGATE**

About Us  
Reports by Region  
FAQ  
Privacy Policy  
TERMS & CONDITIONS  
CONTACT
RECENT POSTS

What is drug pipeline research?  
March 20

How to use market research to bring your idea to life?  
March 11

How to gain business insights using syndicated market research?  
March 10

Source URL: https://www.drugpipeline.net/global-markets-direct/dual-specificity-protein-kinase-ttk-cancer-testis-antigen-96-or-multipolar-1

Links
[1] https://www.drugpipeline.net/region/global